SCHEMBL424121

SCHEMBL424121

CC1CCc2ccccc2N1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 3/20 0.45
BRD4 O60885 4/20 0.43
CREBBP Q92793 3/20 0.43
EP300 Q09472 1/20 0.43
SMYD3 Q9H7B4 1/20 0.41
NPC1 O15118 1/20 0.39
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GFER P55789 1/20 0.39
TSHR P16473 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.38
PDPK1 O15530 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734662 1.00 MTNR1A (0.45) MTNR1ABRD4CREBBPEP300SMYD3
SCHEMBL29683355 1.00 MTNR1A (0.45) MTNR1ABRD4CREBBPEP300SMYD3
SCHEMBL29641564 1.00 MTNR1A (0.45) MTNR1ABRD4CREBBPEP300SMYD3
SCHEMBL4130897 1.00 MTNR1A (0.45) MTNR1ABRD4CREBBPEP300SMYD3
Ammonia Solution, Strong SCHEMBL5054545 0.98 MTNR1A (0.44) MTNR1ABRD4CREBBPEP300SMYD3
SCHEMBL166058 0.88 MAPT (0.43) MTNR1ABRD4CREBBPEP300NPC1
SCHEMBL23812633 0.85 TSHR (0.41) MTNR1ABRD4CREBBPEP300NPC1
SCHEMBL22383643 0.80 MTNR1A (0.43) MTNR1ABRD4CREBBPSMYD3NPC1
SCHEMBL19774297 0.78 MTNR1A (0.47) MTNR1ASMYD3NPC1MAPK13MAPK12
SCHEMBL1736809 0.78 CREBBP (0.55) BRD4CREBBPEP300TSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 754 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581069-A1 ANAEROBICALLY CURABLE COMPOSITIONS Henkel AG & Co. KGaA (DE) 2025-07-09 EP claimed
US-20250197690-A1 ANAEROBICALLY CURABLE COMPOSITIONS HENKEL AG & CO KGAA (DE) 2025-06-19 US claimed
CN-118204084-A Preparation method of silicon oxide modified metal-based catalyst and application of silicon oxide modified metal-based catalyst in preparation of cyclic amine compounds 浙江恒逸石化研究院有限公司 2024-06-18 CN claimed
WO-2024046703-A1 ANAEROBICALLY CURABLE COMPOSITIONS HENKEL AG & CO. KGAA (DE) 2024-03-07 WO claimed
EP-4326789-A1 ANAEROBICALLY CURABLE COMPOSITIONS Henkel AG & Co. KGaA (DE) 2024-02-28 EP claimed
US-20240052219-A1 ANAEROBICALLY CURABLE COMPOSITIONS HENKEL AG & CO KGAA (DE) 2024-02-15 US claimed
US-11891512-B2 Redox curable compositions and methods of manufacture thereof HENKEL AG & CO. KGAA (DE) 2024-02-06 US claimed
CN-116621776-A Preparation method of 2-methylquinoline 遵义医科大学 2023-08-22 CN claimed
CN-116376858-A Application of monoamine oxidase from microorganism as catalyst in preparation of quinoline or quinoline derivative 浙江大学杭州国际科创中心 2023-07-04 CN claimed
US-20230147662-A1 REDOX CURABLE COMPOSITIONS AND METHODS OF MANUFACTURE THEREOF HENKEL AG & CO. KGAA (DE) 2023-05-11 US claimed
WO-2012112758-A2 VIRTUAL HYDROGEN STORAGE PROCESSES AND RELATED CATALYSTS AND SYSTEMS YALE UNIVERSITY (US) 2012-08-23 WO claimed
WO-2009024095-A1 METHOD OF MAKING AND ADMINISTERING QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS THE HONG KONG POLYTECHNIC UNIVERSITY (CN) 2009-02-26 WO claimed
US-20090054482-A1 Method of making and administering quinoline derivatives as anti-cancer agents THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2009-02-26 US claimed
EP-0495250-B1 Cationic 1,3,4 thiadiazole dyes BAYER AG (DE) 1996-01-31 EP claimed
EP-0495250-A1 Cationic 1,3,4 thiadiazole dyes BAYER AG (DE) 1992-07-22 EP claimed
US-4460760-A ADHESIVES OKURA KOGYO KABUSHIKI KAISHA (JP) 1984-07-17 US claimed
US-4447563-A Anaerobically curable composition and process for preparation thereof OKURA KOGYO KABUSHIKI KAISHA (JP) 1984-05-08 US claimed
EP-0006540-B1 N-DICHLOROACETYL-1,2,3,4-TETRAHYDROQUINALDINE, PROCESS FOR OBTAINING IT, ITS USE FOR PREVENTING CROPS FROM BEING DAMAGED BY HERBICIDES AND SELECTIVE HERBICIDAL COMPOSITIONS BASED ON N-DICHLOROACETYL-1,2,3,4-TETRAHYDROQUINALDINE AND HERBICIDAL ACETANILIDES OR THIOLCARBAMATES BAYER AG (DE) 1981-10-07 EP claimed
EP-0023306-A1 N-(Alpha-chloropropionyl)-1,2,3,4-tetrahydro-quinaldine, process for its preparation and its use as antidote in preventing damage to crops by herbicides BAYER AG (DE) 1981-02-04 EP claimed
EP-0006540-A1 N-Dichloroacetyl-1,2,3,4-tetrahydroquinaldine, process for obtaining it, its use for preventing crops from being damaged by herbicides and selective herbicidal compositions based on N-dichloroacetyl-1,2,3,4-tetrahydroquinaldine and herbicidal acetanilides or thiolcarbamates BAYER AG (DE) 1980-01-09 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054482-A1 Method of making and administering quinoline derivatives as anti-cancer agents HCCS, GLS2, NQO1 MTNR1A 1442/4885BRD4 99/4885CREBBP 2023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.